amiselimod vs Ponesimod
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: S1P receptor · full Ulcerative Colitis pipeline
amiselimod
Developed by Bausch Health under a licence from Tanabe Pharma Corporation
NCT04857112 · Phase 2 · completed
This trial randomly assigned 322 people with ulcerative colitis to one of two amiselimod doses or placebo, with participants and investigators unaware of assignment. The primary measure was change in the modified Mayo Score, which combines the appearance of the bowel lining at endoscopy with clinical disease activity. Scores fell by 2.3 points on amiselimod against 1.6 points on placebo (p=0.002).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Change from Baseline in the modified Mayo Score at Day 85 (Baseline to Day 85): Change from baseline in modified Mayo Score at Day 85: amiselimod -2.3 vs placebo -1.6 (p=0.002) (met)
Result source: NCT04857112
Ponesimod
Marketed by Vanda Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2029 · NCT07686081 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | amiselimod | Ponesimod |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Trial running · NCT07686081 |
| Clinical remission (maintenance) | —Not reported | —Trial running · NCT07686081 |
| Clinical response (induction) | —Not reported | —Trial running · NCT07686081 |
| Endoscopic improvement (induction) | —Not reported | —Trial running · NCT07686081 |
| Corticosteroid-free remission (maintenance) | —Not reported | —Trial running · NCT07686081 |
Clinical remission (induction)
- amiselimod
- —Not reported
- Ponesimod
- —Trial running · NCT07686081
Clinical remission (maintenance)
- amiselimod
- —Not reported
- Ponesimod
- —Trial running · NCT07686081
Clinical response (induction)
- amiselimod
- —Not reported
- Ponesimod
- —Trial running · NCT07686081
Endoscopic improvement (induction)
- amiselimod
- —Not reported
- Ponesimod
- —Trial running · NCT07686081
Corticosteroid-free remission (maintenance)
- amiselimod
- —Not reported
- Ponesimod
- —Trial running · NCT07686081
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Ponesimod: no structured comparison results are available for Ulcerative Colitis.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
amiselimod
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: amiselimod's landscape · Ponesimod's landscape